Get the Stockscreener App
0.97
5.66%
-0.09
Atyr Pharma Inc stock is traded at $0.97, with a volume of 1.69M.
It is down -5.66% in the last 24 hours and down -83.42% over the past month.
aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can cause to fibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis.
See More
Previous Close:
$1.06
Open:
$1.065
24h Volume:
1.69M
Relative Volume:
0.16
Market Cap:
$95.38M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
+21.27%
1M Performance:
-83.42%
6M Performance:
-66.33%
1Y Performance:
-55.16%
1-Day Range:
$0.96
$1.08
1-Week Range:
$0.7995
$1.12
52-Week Range:
$0.6816
$7.2904
Atyr Pharma Inc Stock (ATYR) Company Profile
Name
Atyr Pharma Inc
Sector
Industry
Phone
(858) 731-8389
Address
10240 SORRENTO VALLEY ROAD, SAN DIEGO
Compare ATYR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ATYR
Atyr Pharma Inc
|
0.9734 | 103.87M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
406.02 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
461.69 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
543.75 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
796.67 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
326.40 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Atyr Pharma Inc Stock (ATYR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-16-25 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Sep-15-25 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Sep-15-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Sep-15-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Sep-15-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Feb-18-25 | Initiated | Leerink Partners | Outperform |
| Jan-06-25 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-04-24 | Initiated | Wells Fargo | Overweight |
| Sep-05-24 | Initiated | Jefferies | Buy |
| Jul-05-23 | Downgrade | Oppenheimer | Outperform → Perform |
| Oct-12-21 | Initiated | RBC Capital Mkts | Outperform |
| Sep-21-21 | Initiated | Piper Sandler | Overweight |
| May-10-21 | Initiated | Laidlaw | Buy |
| Aug-17-20 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Mar-04-20 | Initiated | ROTH Capital | Buy |
| Mar-02-20 | Initiated | Oppenheimer | Outperform |
| Feb-14-18 | Downgrade | JP Morgan | Neutral → Underweight |
| Sep-07-17 | Initiated | Piper Jaffray | Overweight |
| Dec-13-16 | Downgrade | JP Morgan | Overweight → Neutral |
| Dec-16-15 | Initiated | Citigroup | Neutral |
| Jun-01-15 | Initiated | Citigroup | Buy |
| Jun-01-15 | Initiated | JP Morgan | Overweight |
View All
Atyr Pharma Inc Stock (ATYR) Latest News
Why aTyr Pharma Inc. stock could see breakout soonStock Surge & Scalable Portfolio Growth Ideas - newser.com
What catalysts could drive aTyr Pharma Inc. stock higherEarnings Beat & Reliable Price Breakout Signals - newser.com
Levi & Korsinsky Urges aTyr Pharma, Inc. (ATYR) Shareholders to Act Before Lead Plaintiff Deadline December 8, 2025 - ACCESS Newswire
Securities Lawsuit Alert: aTyr Pharma, Inc. (ATYR) InvestorsContact Levi & Korsinsky Before December 8, 2025 - ACCESS Newswire
aTyr Pharma Sees Significant Rebound in Premarket Trading - timothysykes.com
ATYR INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC - GlobeNewswire
INVESTOR DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of aTyr Pharma - Business Wire
ROSEN, A RANKED AND LEADING LAW FIRM, Encourages aTyr - GlobeNewswire
ROSEN, A RANKED AND LEADING LAW FIRM, Encourages aTyr Pharma, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - GlobeNewswire Inc.
Insider Spends US$912k Buying More Shares In ATyr Pharma - 富途牛牛
Independent Director of aTyr Pharma Paul Schimmel Buys 91% More Shares - Yahoo Finance
What makes aTyr Pharma Inc. (471A) stock appealing to growth investorsWeekly Investment Summary & Safe Capital Growth Tips - newser.com
Measuring aTyr Pharma Inc.’s beta against major indices2025 Support & Resistance & Technical Confirmation Trade Alerts - newser.com
aTyr Pharma Rebounds with 7.4% Premarket Surge After Recent Decline - StocksToTrade
ATyr Pharma Faces Investor Suit Over Failed Drug Trial - Law360
Insider Buying: aTyr Pharma (NASDAQ:ATYR) Director Purchases 682,001 Shares of Stock - MarketBeat
ATYR Investor Notice: Robbins LLP Reminds Investors of the Securities Fraud Class Action Against aTyr Pharma, Inc. - GlobeNewswire Inc.
ATyr Pharma, Inc. Sued for Securities Law ViolationsContact the DJS Law Group to Discuss Your Rights – ATYR - MarketScreener
aTyr Pharma, Inc. Sued for Securities Law ViolationsContact the DJS Law Group to Discuss Your Rights – ATYR - The Globe and Mail
ATYR Investors Have Opportunity to Lead aTyr Pharma, Inc. Securities Fraud Lawsuit with the Schall Law Firm - The AI Journal
Levi & Korsinsky Invites Investors to SueWallSt After aTyr Pharma, Inc. Stock Collapse - ACCESS Newswire
Rosen Law Firm Urges aTyr Pharma, Inc. (NASDAQ: ATYR) Stockholders with Losses in Excess of $100K to Contact the Firm for Information About Their Rights - FinancialContent
aTyr Pharma, Inc. (ATYR) Securities Class Action Deadline - GlobeNewswire
Published on: 2025-10-10 09:51:10 - newser.com
aTyr Pharma, Inc. Stock (ATYR) Opinions on Phase 3 Trial Failure - Quiver Quantitative
Trend analysis for aTyr Pharma Inc. this weekJuly 2025 Levels & Technical Buy Zone Confirmations - newser.com
aTyr Pharma Faces Legal Storm After Trial Failure - TipRanks
ATyr Pharma Rated as Overweight at Cantor Fitzgerald on Efzofitimod Expectations - MSN
What to expect from aTyr Pharma Inc. in the next 30 days2025 Market WrapUp & Stock Timing and Entry Methods - newser.com
Why aTyr Pharma Inc. (471A) stock appears on watchlistsEntry Point & Community Verified Trade Signals - newser.com
Stockholder Alert: Robbins LLP Informs aTyr Pharma, Inc. Stockholders that a Class Action Lawsuit was Filed Against the Company - Eastern Progress
Director Makes Major Investment in aTyr Pharma! - TipRanks
aTyr Pharma, Inc.’s (ATYR) Failed Drug Trial Spurs Securities Lawsuit — Hagens Berman - The Malaysian Reserve
aTyr Pharma, Inc.'s (ATYR) Failed Drug Trial Spurs Securities Lawsuit -- Hagens Berman - PR Newswire
aTyr Pharma, Inc. (ATYR) Faces Investor Scrutiny After - GlobeNewswire
Atyr pharma director Schimmel buys shares worth $911k By Investing.com - Investing.com UK
Atyr pharma director Schimmel buys shares worth $911k - Investing.com India
aTyr Pharma (NASDAQ:ATYR) Given Sell (D-) Rating at Weiss Ratings - MarketBeat
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors - GlobeNewswire
aTyr Pharma Investor Sues Over Drug Study’s Endpoint Miss (1) - Bloomberg Law News
Is aTyr Pharma Inc a good long term investmentMarket Timing Techniques & Small Investment Trading Growth - earlytimes.in
Can aTyr Pharma Inc. (471A) stock sustain revenue momentumTrade Entry Report & Verified Entry Point Signals - newser.com
Evaluating aTyr Pharma Inc. with trendline analysisJuly 2025 Recap & Community Verified Trade Signals - newser.com
Why aTyr Pharma Inc. (471A) stock is favored by hedge funds2025 Institutional Moves & Weekly High Potential Alerts - newser.com
What recovery options are there for aTyr Pharma Inc.Portfolio Gains Summary & Breakout Confirmation Alerts - newser.com
Ongoing aTyr Pharma, Inc. (ATYR) Investigation: Protect Your RightsContact Levi & Korsinsky - ACCESS Newswire
ATYR stock analysis: ATYR up 19.57% today, what happened to Atyr Pharma? - Markets.com
What drives aTyr Pharma Inc stock priceShort Interest Overview & Explosive Growth Trading - earlytimes.in
ATYR ALERT: Levi & Korsinsky Investigates aTyr Pharma, Inc. For Possible Securities Fraud Violations - ACCESS Newswire
Will aTyr Pharma Inc. rebound enough to break evenQuarterly Risk Review & Free Weekly Chart Analysis and Trade Guides - newser.com
Quantitative breakdown of aTyr Pharma Inc. recent move2025 Trading Volume Trends & High Accuracy Swing Trade Signals - newser.com
Atyr Pharma Inc Stock (ATYR) Financials Data
There is no financial data for Atyr Pharma Inc (ATYR). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
Atyr Pharma Inc Stock (ATYR) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| SCHIMMEL PAUL | Director |
Oct 09 '25 |
Buy |
0.94 |
317,999 |
299,364 |
1,413,023 |
| Gross Jane A | Director |
Mar 17 '25 |
Buy |
4.00 |
3,750 |
15,000 |
9,750 |
| Broadfoot Jill Marie | Chief Financial Officer |
Feb 04 '25 |
Sale |
3.78 |
1,254 |
4,740 |
31,763 |
| DENYES NANCY | General Counsel |
Feb 04 '25 |
Sale |
3.78 |
899 |
3,398 |
26,555 |
2.36%
0.82%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):